Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders

[1]  A. Cross,et al.  Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial , 2023, The Lancet Neurology.

[2]  M. T. Bendicho,et al.  Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review. , 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[3]  S. Braunstein,et al.  Management of Adverse Radiation Effect Associated with Stereotactic Radiosurgery of Brain Metastasis in Multiple Sclerosis , 2022, Advances in radiation oncology.

[4]  K. Galetta,et al.  Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors , 2022, Multiple sclerosis.

[5]  Nathan Kim,et al.  An Interesting Case Report of Myasthenia Gravis Exacerbation Induced by Durvalumab , 2022, Cureus.

[6]  Andrew Snavely,et al.  Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases , 2022, Journal of the Neurological Sciences.

[7]  A. Kulasinghe,et al.  Immune Checkpoint Inhibitors in Cancer Therapy , 2022, Current oncology.

[8]  R. Garje,et al.  Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge , 2022, Biomedicines.

[9]  A. Guminski,et al.  Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma , 2022, Oxford medical case reports.

[10]  S. Wen,et al.  CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review , 2021, Journal of the Neurological Sciences.

[11]  E. Wallen,et al.  Complete pathologic response to pembrolizumab and axitinib in a patient with sarcomatoid RCC and ocrelizumab-treated multiple sclerosis. , 2021, Urology.

[12]  J. Hassel,et al.  How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors , 2021, ESMO open.

[13]  A. Huttner,et al.  Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report , 2021, JTO clinical and research reports.

[14]  Hamish Patel,et al.  Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma , 2021, Cureus.

[15]  Baolin Zhang,et al.  Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics , 2021, The AAPS Journal.

[16]  M. Simabukuro,et al.  Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature , 2020, Frontiers in Neurology.

[17]  Y. Uesaka,et al.  Pembrolizumab on pre-existing inclusion body myositis: a case report , 2020, BMC Rheumatology.

[18]  T. Hundsberger,et al.  Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients , 2020, Cancer Immunology, Immunotherapy.

[19]  H. Abboud,et al.  Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events. , 2020, Multiple sclerosis and related disorders.

[20]  C. Klein,et al.  Neurological autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. , 2020, Neurology.

[21]  V. Calvo,et al.  Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data , 2020, Lung cancer management.

[22]  J. Larkin,et al.  Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Yokoyama,et al.  Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis , 2020, eNeurologicalSci.

[24]  Douglas B. Johnson,et al.  Neurologic complications of immune checkpoint inhibitors , 2020, Expert opinion on drug safety.

[25]  Doreen T. Ho,et al.  Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature , 2020, Journal of Neuroimmunology.

[26]  J. Honnorat,et al.  Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study , 2019, Journal of Immunotherapy for Cancer.

[27]  M. Suarez‐Almazor,et al.  Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[28]  C. Tornatore,et al.  Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations , 2019, Neurology and Therapy.

[29]  M. Filippi,et al.  Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer , 2019, Journal of Neurology.

[30]  A. Pruitt,et al.  A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes , 2019, Journal of Neuroimmunology.

[31]  B. Soliven,et al.  Severe Relapse of Vaccine-Induced Guillain-Barré Syndrome After Treatment With Nivolumab. , 2019, Journal of clinical neuromuscular disease.

[32]  D. Schadendorf,et al.  Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors? , 2019, Journal of Immunotherapy for Cancer.

[33]  J. Villano,et al.  Multiple sclerosis outcomes after cancer immunotherapy , 2019, Clinical and Translational Oncology.

[34]  D. Lacomis,et al.  Clinical spectrum of neuromuscular complications after immune checkpoint inhibition , 2019, Neuromuscular Disorders.

[35]  M. Fakih,et al.  Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. , 2018, Journal of gastrointestinal oncology.

[36]  J. Hara,et al.  Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung. , 2018, Clinical lung cancer.

[37]  R. Bedlack,et al.  Refractory myasthenia gravis exacerbation triggered By pembrolizumab , 2018, Muscle & nerve.

[38]  C. Ficorella,et al.  Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome , 2018, Case reports in oncological medicine.

[39]  N. Girard,et al.  Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. , 2018, European journal of cancer.

[40]  A. Gesierich,et al.  Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders , 2018, Cancer Immunology, Immunotherapy.

[41]  M. Ichinose,et al.  Relapsed Myasthenia Gravis after Nivolumab Treatment , 2018, Internal medicine.

[42]  M. Akiyama,et al.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study , 2018, Journal of the Endocrine Society.

[43]  M. Suarez‐Almazor,et al.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.

[44]  P. Hagmann,et al.  Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[45]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[46]  R. Hohlfeld,et al.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives , 2017, Nature Reviews Neurology.

[47]  X. Mariette,et al.  Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment , 2017, Annals of the rheumatic diseases.

[48]  R. Hughes,et al.  Corticosteroids for Guillain-Barré syndrome. , 2016, The Cochrane database of systematic reviews.

[49]  Y. Zakharia,et al.  Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease , 2016, Journal of investigative medicine high impact case reports.

[50]  R. A. González,et al.  P04.07 Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab , 2016 .

[51]  R. Sullivan,et al.  Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Yuebing Li,et al.  Myasthenia gravis exacerbation associated with pembrolizumab , 2016, Muscle & nerve.

[53]  C. Berking,et al.  CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis , 2016, Annals of neurology.

[54]  E. Waubant,et al.  Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. , 2016, JAMA neurology.

[55]  I. Yang,et al.  Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab , 2016, Muscle & nerve.

[56]  A. Vortmeyer,et al.  CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment , 2016, Neurology.

[57]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[58]  M. Akiyama,et al.  Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis , 2016, Nagoya journal of medical science.

[59]  T. Scott,et al.  Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma , 2015, Multiple sclerosis.

[60]  M. Suarez‐Almazor,et al.  Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience , 2014, Oncogene.

[61]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and autoimmune disease , 2014, Journal of Immunotherapy for Cancer.

[62]  G. Cutter,et al.  Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? , 2014, Muscle & nerve.

[63]  I. Lowy,et al.  Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma. , 2018, The oncologist.

[64]  P. Bonomi,et al.  Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. , 2017, Journal of neuromuscular diseases.